Virax Biolabs (VRAX) - 2025 Q2 - Quarterly Report

Exhibit 99.1 Unaudited Condensed Consolidated Interim Financial Statements as of September 30, 2024 Page Condensed Consolidated Statements of Financial Position as of September 30, 2024 and March 31, 2024 (Unaudited) F-3 Condensed Consolidated Statements of Profit and Loss and Other Comprehensive Loss for the Six Months Ended September 30, 2024 and 2023 (Unaudited) F-4 Condensed Consolidated Statements of Changes in Equity for the Six Months Ended September 30, 2024 and 2023 (Unaudited) F-5 Condensed Consol ...